Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from FDA

Abbott again halting baby formula production at its Michigan facility after flooding

Less than two weeks after restarting formula production at its Michigan facility, Abbott has again had to halt manufacturing there amid flooding.

Chicago Tribune

Walgreens Launches Clinical Trial Business

Walgreens Boots Alliance Inc (NASDAQ:WBA) has launched its clinical trial business to redefine the patient experience and increase access and retention in sponsor-led drug development research. Walgreens will combine the flexible clinical trial model with its vast data on patient insights, partner-enabled health and technology capabilities, and in-person and virtual care options. The…

Benzinga

White House Consults with Law Professors in Anticipation of Dobbs Ruling (Updated)

The Biden Administration is apparently considering a range of responses should te Supreme Court overturn Roe v. Wade.

Reason

From analysis to the latest developments in health,
read the most diverse news in one place.

Abbott's baby formula plant closes again after severe storms and flooding

Abbott's Sturgis, Mich., plant was open for less than two weeks before it had to close again after flooding from severe weather. The company said it hopes to resume production in a few weeks.

WEKU

The best time to make a major life decision, according to science

In this edition of Inverse Daily, read about the tarantula nebula, making decisions using science, and more.

Inverse

Baby formula production at Michigan plant delayed by severe flooding

Barely two weeks after production restarted at a Michigan plant that supplies baby formula, flooding in the area has shut down the work as supply continues to dry up nationwide.

Tribune News Service

Senseonics' Next-Gen Eversense E3 Glucose Monitoring System Scores European Approval

Senseonics Holdings Inc (NYSE:SENS) has received CE Mark approval for the next-generation Eversense E3 CGM System. Senseonics' European commercial partner, Ascensia Diabetes Care, will make the improved System, which can be used for up to 6 months, available from Q3 of 2022. The next-generation System offers improved accuracy with the longest-lasting sensor available,…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Checkpoint' Cancer Therapy Shows Almost 55% Response Rate In Skin Cancer Patients

Checkpoint Therapeutics Inc (NASDAQ:CKPT) announced positive interim efficacy results from its registration-enabling trial of cosibelimab, in patients with locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation. The design of the interim analysis incorporated recent FDA feedback and is intended to support the approval of cosibelimab…

Benzinga

Johnson & Johnson Urges FDA To Take Interim Steps As It Continues To Review CBD

The FDA's Science Board has once again reviewed the idea of incorporating cannabinoids into dietary supplements.

Benzinga

More Trouble For Baby Formula Production As Thunderstorms, Flood, Hit Abbott's Troubled Michigan Plant

Just a few weeks after reopening its baby formula Sturgis, Michigan plant, Abbott Laboratories (NYSE:ABT) said it paused EleCare specialty baby formula production after recent thunderstorms flooded part of the facility. The company has informed the FDA and will conduct comprehensive testing with an independent third party to ensure the plant is safe to…

Benzinga

Aquestive Therapeutics Reveals Favorable Data From Epinephrine Trial For Allergies

Aquestive Therapeutics Inc (NASDAQ:AQST) announced topline results from the first three arms of Part 3 of the EPIPHAST study for its AQST-109 epinephrine oral film for allergic reactions, including anaphylaxis. In the first three arms of Part 3, AQST-109 12 mg continued to show rapid absorption with favorable pharmacokinetics. The median time to…

Benzinga

Moderna Plans COVID-19 Vaccine Trial For Infants: WSJ

Moderna Inc (NASDAQ: MRNA) is reportedly planning to evaluate its COVID-19 vaccine in infants aged three months to 6 months.

Benzinga

A major pandemic hurdle is being crossed with young kids getting vaccine access

Parents of infants and toddlers are a major step closer to having front-line protection against COVID after a key FDA committee on Wednesday unanimously recommended authorizing vaccines for kids as young as six months.

Axios

71 Biggest Movers From Yesterday

Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 225% to close at $4.68 on Wednesday after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity services contract with a potential value of $3.5 billion.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Axios

Abbott halts production at Michigan baby formula plant after storm causes flooding

The beleagured Sturgis plant only resumed production less than 2 weeks ago.

The Independent UK

AP under fire for using photos of children in pain to report on youth vaccine approval

Children under the age of five still can’t get vaccinated yet in US

France 24

US FDA panel backs first Covid-19 jabs for children under five

The first COVID-19 shots for U.S. infants, toddlers and preschoolers moved a step closer Wednesday.

Chicago Tribune

FDA panel recommends COVID vaccines for little kids, but questions remain about where they’ll be available

CHICAGO — Mary MacMillan is eager to get her 2-year-old son vaccinated against COVID-19, once vaccines are authorized for young kids. But she has a lot of questions about how to get the shots.

Get all your
news in one place.

100’s of premium titles.
One news app.

Roll Call

FDA panel gives green light to pediatric COVID-19 vaccines - Roll Call

Those under 5 are the last group eligible for the Moderna and Pfizer vaccines, and shots could go out as soon as next week.

ABC News

America's FDA panel backs Moderna and Pfizer COVID-19 vaccines for children under five. Here's what that means

Advisors to US federal regulators are backing two COVID-19 vaccines for children as young as six months old, with the final decision to be watched closely by Australian health officials, along with parents eager to put pandemic concerns behind them.

Tribune News Service

Moderna’s COVID shot for youngest children gets FDA panel’s support

Moderna Inc.’s COVID-19 vaccine for infants and toddlers won the support of a panel of U.S. regulatory advisers, putting parents one step closer to being able to protect their youngest against COVID-19 for the first time.

Inverse

FDA just authorized Covid-19 vaccines for kids under 5. Here’s what parents need to know

An outside panel of experts for the FDA recommended both the Moderna and Pfizer vaccine for kids under 5. Shortly after, the FDA granted a EUA.

Axios

FDA committee recommends COVID shots for kids as young as 6 months

Children younger than 5 are the last group without access to the shots.

Benzinga

Why ACADIA Pharmaceuticals Shares Are Trading Higher Today?

Ahead of Acadia Pharmaceuticals Inc's (NASDAQ:ACAD) FDA AdComm meeting on Friday, the agency officials released their briefing documents, revealing a mixed bag of opinions. The company's resubmitted supplemental New Drug Application for pimavanserin for hallucinations and delusions associated with Alzheimer's disease psychosis (ADP) has a target action date of August 4. Initially, the FDA…

The Independent UK

Fisher-Price issues warning after 13 infant deaths from rockers - what you need to know

No recall has been issued for the product, but parents are advised not to let newborns and toddlers sleep in the rockers

1 … 178 179 180 181

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

317 stories

Chicago Public Schools

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.